Canadian Journal of Anaesthesia

, Volume 36, Issue 1, pp 64–74

monoamine oxidase inhibitors revisited

Authors

  • Douglas G. Wells
    • Department of AnaesthesiaAmalgamated Melbourne and Essendon Hospitals
    • Department of Anaesthesia C/O Post OfficeThe Royal Melbourne Hospital
  • Andrew R. Bjorksten
    • Department of AnaesthesiaAmalgamated Melbourne and Essendon Hospitals
Review article

DOI: 10.1007/BF03010890

Cite this article as:
Wells, D.G. & Bjorksten, A.R. Can J Anaesth (1989) 36: 64. doi:10.1007/BF03010890

Conclusion

Until recently, traditional teaching has been to discontinue MAOI therapy two to three weeks before surgery. The literature and texts relating to the concurrent use of MAOI’s with anaesthesia are confusing, outdated and often contradictory. Significant adverse drug reactions can and have occurred in a minority of patients receiving MAOI’s. The true incidence of such reactions is unknown. While there are several recent clinical reports indicating the safety of these agents in combination with anaesthesia, only small numbers of patients are described in each series. Until it is possible to define those individual patients in whom adverse reactions are likely to occur, all patients must be assumed to be at some level of potential risk.

However, assuming administration in appropriate doses and for appropriate indications, patients can and likely should continue to receive MAOI therapy. A final decision on the administration of anaesthesia in the presence of MAOI therapy can only be made by an anaesthetist familiar with the pharmacology of the MAO system and its inhibitors.

Key words

interactions (drug): monoamine oxidase inhibitorssympathomimetic aminesmeperidinebarbituratespharmacology: monamine oxidase inhibitors
Download to read the full article text

Copyright information

© Canadian Anesthesiologists 1989